• M Berk, F Kapczinski, A C Andreazza, O M Dean, F Giorlando, M Maes, M Yücel, C S Gama, S Dodd, B Dean, P V S Magalhães, P Amminger, P McGorry, and G S Malhi.
• Department of Clinical and Biomedical Sciences, University of Melbourne, Victoria 3010, Australia. mikebe@barwonhealth.org.au
• Neurosci Biobehav Rev. 2011 Jan 1; 35 (3): 804-17.

AbstractThere is now strong evidence of progressive neuropathological processes in bipolar disorder (BD). On this basis, the current understanding of the neurobiology of BD has shifted from an initial focus on monoamines, subsequently including evidence of changes in intracellular second messenger systems and more recently to, incorporating changes in inflammatory cytokines, corticosteroids, neurotrophins, mitochondrial energy generation, oxidative stress and neurogenesis into a more comprehensive model capable of explaining some of the clinical features of BD. These features include progressive shortening of the inter-episode interval with each recurrence, occurring in consort with reduced probability of treatment response as the illness progresses. To this end, emerging data shows that these biomarkers may differ between early and late stages of BD in parallel with stage-related structural and neurocognitive alterations. This understanding facilitates identification of rational therapeutic targets, and the development of novel treatment classes. Additionally, these pathways provide a cogent explanation for the efficacy of seemingly diverse therapies used in BD, that appear to share common effects on oxidative, inflammatory and neurotrophic pathways.Copyright © 2010 Elsevier Ltd. All rights reserved.

18 keywords...

hide…